Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Dermatologic 1

Conditions

Anemia, Iron-Deficiency 2Anemia 2Plexosarcoma 1Neoplasms 1Melanoma 1Lymphoma, Follicular 1Gastrointestinal Stromal Tumors 1Crohn Disease 1Colitis, Ulcerative 1

Interventions

Darbepoetin alfa 19Epoetin Alfa 17ACE-011 4Cyclosporine 3Busulfan 3luspatercept 2fludarabine phosphate 2fludarabine 2ferric carboxymaltose 2epoetin beta 2continuous erythropoietin receptor activator 2Methotrexate 2Iron-Dextran Complex 2Filgrastim 2Cyclophosphamide 2vactosertib 1thymoglobulin 1ruxolitinib 1roxadustat 1peginesatide 1pegfilgrastim 1niraparib 1leridistim 1iron isomaltoside 1000 1hematide 1ferric gluconate 1eltrombopag 1angiotensin I (1-7) 1Therapeutics 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Anemia × Iron-Dextran Complex × Clear all
NCT06508827 2025-07-09

Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

Indiana University

Phase 2 Withdrawn
Classical hematologyDermatologic

Anemia, Melanoma, Anemia, Iron-Deficiency

NCT00401544 2014-01-29

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Amgen

Phase 2 Completed
243 enrolled 26 charts
Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡